Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM336 + Daratumumab + Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
NCT07830485Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
A Phase 2 trial of gamgertamig in multiple myeloma (MM), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
gamgertamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07830485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07830485.